Frequently Asked Questions
In 2022, the North America Arrhythmia Management System (AMS) market was estimated to be worth USD 3.7 billion.
The North America Arrhythmia Management System (AMS) market is anticipated to develop at a CAGR of 6.60% between 2023 and 2030, reaching USD 5.78 billion in 2030.
Electrocardiogram (ECG) is the leading segment by test equipment.
Sinus bradycardia is the leading segment by site of origin atrial.
Supraventricular tachycardias is expected to have the highest CAGR during the forecast period.
The United States is driving the growth of the North America Arrhythmia Management System (AMS) industry.
The top players include Applied Cardiac Systems, AliveCor, Biotronik, and Biotricity. Other major players include GE Healthcare, iRhythm Technologies, and Koninklijke Philips N.V.
The key factors driving the market growth are the rising prevalence of arrhythmia and the growing senior population.
The high cost of AMS devices and a scarcity of qualified healthcare workers limit market growth.
The market’s significant opportunities are the growing demand for remote patient monitoring and telemedicine solutions and a focus on patient education and engagement.